# Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

> **NCT04857697** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 6 (actual)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Breast Adenocarcinoma
- Stage I Lung Cancer AJCC v8
- Stage II Lung Cancer AJCC v8
- Stage III Lung Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Probiotic
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT04857697
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2023-03-08
- **Final completion:** 2023-03-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857697, "Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04857697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*